🏥 治験ポータル
← 治験一覧に戻る

脳や脊髄に関連する問題を除く、身体に既知または疑われる問題のある人を対象に、ガドクアトランの効果と安全性を既存のMRI造影剤と比較する研究

基本情報

NCT ID
NCT05915728
ステータス
完了
試験のフェーズ
第3相
試験タイプ
介入
目標被験者数
404
治験依頼者名
Bayer

概要

Researchers are looking for a better way to help people with any known or suspected problems (except brain or spinal cord-related problems) scheduled for a "contrast-enhanced" Magnetic Resonance Imaging (MRI). MRI is used by doctors to create detailed images of the inside of the body to identify health problems. Sometimes doctors need to inject contrast agent into a patient's vein to perform a so called "contrast-enhanced" MRI (CE-MRI). Such CE-MRI examinations may support doctors to identify certain health problems or improve the evaluation. The contrast agents commonly used in MRI are gadolinium-based contrast agents (GBCAs). GBCAs contain a "rare earth" element called gadolinium (Gd). Gadoquatrane is a new contrast agent under development with a lower amount of Gd needed per CE-MRI. The main purpose of this study is to learn whether CE-MRI scans with gadoquatrane work better than MRI scans without the use of a contrast agent (GBCA). The researchers will compare the ability to detect known or suspected problems (except brain or spinal cord-related problems) with gadoquatrane-MRI scans to plain-MRI scans without the use of a contrast agent. The participants will undergo 2 MRI scans, one with gadoquatrane and one with currently used GBCA. Both contrast agents will be injected into the vein. Each participant will be in the study for between 6 and 42 days with up to 7 doctor visits. At the start or during the study, the doctors and their study team will: * take blood and urine samples * do physical examinations * check blood pressure and heart rate * review the MRI scans obtained in the study and decide on the diagnosis * ask the participants questions about how they are feeling and what adverse events they are having. An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatments.

対象疾患

Contrast Enhancement in Magnetic Resonance ImagingNon-central Nervous System Pathology

介入

Gadoquatrane (BAY1747846)(DRUG)
Gadobutrol(DRUG)
Gadoterate meglumine(DRUG)
Gadoteridol(DRUG)

依頼者(Sponsor)

実施施設 (13)

函館中央病院

Hakodate, Hokkaido, Japan

医療法人徳洲会岸和田徳洲会病院

Kishiwada, Osaka, Japan

独立行政法人国立病院機構関門医療センター

Shimonoseki, Yamaguchi, Japan

産業医科大学病院

Kitakyushu, Fukuoka, Japan

独立行政法人労働者健康安全機構東北労災病院

Yonago, Tottori, Japan

独立行政法人国立病院機構金沢医療センター

Kanazawa, Ishikawa-ken, Japan

地方独立行政法人 大阪府立病院機構 大阪国際がんセンター

Osaka, Japan

JCHO Kyushu Hospital

Kitakyushu, Fukuoka, Japan

北海道大学病院

Sapporo, Hokkaido, Japan

兵庫県立西宮病院

Nishinomiya, Hyōgo, Japan

社会医療法人 財団 中村病院

Fukuoka, Japan

高松赤十字病院

Takamatsu, Kagawa-ken, Japan

公立松任石川中央病院

Hakusan, Ishikawa-ken, Japan